Search results for "Tumor microenvironment."

showing 10 items of 307 documents

Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology

2020

Bone remodeling is uncoupled in the multiple myeloma (MM) bone marrow niche, resulting in enhanced osteoclastogenesis responsible of MM-related bone disease (MMBD). Several studies have disclosed the mechanisms underlying increased osteoclast formation and activity triggered by the various cellular components of the MM bone marrow microenvironment, leading to the identification of novel targets for therapeutic intervention. In this regard, recent attention has been given to non-coding RNA (ncRNA) molecules, that finely tune gene expression programs involved in bone homeostasis both in physiological and pathological settings. In this review, we will analyze major signaling pathways involved …

0301 basic medicinelcsh:QH426-470Bone diseasenon-coding RNAReviewBiologyBiochemistryBone remodeling03 medical and health sciences0302 clinical medicineOsteoclastmicroRNAGeneticsmedicinetumor microenvironmentMolecular BiologyMultiple myelomamiRNAlong non-coding RNAmedicine.diseaseNon-coding RNALong non-coding RNAmultiple myelomalcsh:Genetics030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchbone diseaseBone marrowNon-Coding RNA
researchProduct

ROS and Lipid Droplet accumulation induced by high glucose exposure in healthy colon and Colorectal Cancer Stem Cells

2020

Lipid Droplets (LDs) are emerging as crucial players in colon cancer development and maintenance. Their expression has been associated with high tumorigenicity in Cancer Stem Cells (CSCs), so that they have been proposed as a new functional marker in Colorectal Cancer Stem Cells (CR-CSCs). They are also indirectly involved in the modulation of the tumor microenvironment through the production of pro-inflammatory molecules. There is growing evidence that a possible connection between metabolic alterations and malignant transformation exists, although the effects of nutrients, primarily glucose, on the CSC behavior are still mostly unexplored. Glucose is an essential fuel for cancer cells, an…

0301 basic medicinelcsh:QH426-470Colorectal cancerColorectal cancer stem cellsSettore MED/50 - Scienze Tecniche Mediche ApplicateLipid dropletBiochemistryMalignant transformation03 medical and health sciences0302 clinical medicineCancer stem cellLipid dropletFull Length ArticlemedicineCholesterol metabolismMolecular BiologyOncogeneGenetics (clinical)PI3K/AKT/mTOR pathwaySettore MED/04 - Patologia Generalelcsh:R5-920Tumor microenvironmentChemistryPI3K-AKTColorectal cancer stem cellCell BiologyOncogenesmedicine.diseaseLipid droplets3. Good healthlcsh:GeneticsSettore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinica030104 developmental biologyOxidative stress030220 oncology & carcinogenesisFatty acid metabolismCancer cellCancer researchOxidative streSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioStem cellHigh glucoselcsh:Medicine (General)Genes & Diseases
researchProduct

Innovative Therapy, Monoclonal Antibodies and Beyond

2017

IF 6.794; International audience; The seventh Edition of "Innovative Therapy, Monoclonal Antibodies and Beyond" Meeting took place in Milan, Italy, on January 27, 2017. The two sessions of the meeting were focused on: 1) Preclinical assays and novel biotargets; and 2) monoclonal antibodies, cell therapies and targeted molecules. Between these two sessions, a lecture entitled "HLA-antigens modulation and response to immune checkpoint inhibitor immunotherapy" was also presented. Despite the impressive successes in cancer immunotherapy in recent years, the response to immune based interventions occurs only in a minority of patients (∼20%). Several basic and translational mechanisms of resistan…

0301 basic medicinemedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmunology[SDV.CAN]Life Sciences [q-bio]/CancerMonoclonal antibodyGeneral Biochemistry Genetics and Molecular Biology[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineImmune systemCancer immunotherapymedicineImmunology and AllergyTumor microenvironmentbusiness.industryImmunotherapyImmune checkpoint3. Good healthOncolytic virus030104 developmental biology030220 oncology & carcinogenesisImmunologyCancer researchImmunogenic cell deathbusiness
researchProduct

The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38

2018

The relationship between bone and immune cells is well established both in physiological and pathological conditions. Multiple myeloma (MM) is a plasma cell malignancy characterized by an increase of number and activity of osteoclasts (OCLs) and a decrease of osteoblasts (OBs). These events are responsible for bone lesions of MM patients. OCLs support MM cells survival in vitro and in vivo. Recently, the possible role of OCLs as immunosuppressive cells in the MM BM microenvironment has been underlined. OCLs protect MM cells against T cell-mediated cytotoxicity through the expression of several molecules including programmed death-ligand (PD-L) 1, galectin (Gal) 9, CD200, and indoleamine-2,3…

0301 basic medicinemedicine.drug_classT-LymphocytesT cellImmunologyOsteoclastsPlasma cellCD38Monoclonal antibodyImmunomodulation03 medical and health sciencesImmune systemOsteogenesisOsteoclastTumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyGalectinMembrane GlycoproteinsChemistryAntibodies MonoclonalOsteoblastADP-ribosyl Cyclase 1030104 developmental biologymedicine.anatomical_structureCancer researchMultiple MyelomaImmunology Letters
researchProduct

Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells

2021

Abstract Regulatory T (Treg) cells, which are essential for maintaining self-tolerance, inhibit anti-tumor immunity, consequently hindering protective cancer immunosurveillance, and hampering effective anti-tumor immune responses in tumor-bearing hosts. Here, we show that depletion of Treg cells via targeting glycoprotein A repetitions predominant (GARP) induces effective anti-tumor immune responses. GARP was specifically expressed by highly suppressive Treg cells in the tumor microenvironment (TME) of multiple cancer types in humans. In the periphery, GARP was selectively induced in Treg cells, but not in effector T cells, by polyclonal stimulation. DS-1055a, a novel afucosylated anti-huma…

0301 basic medicinemedicine.drug_classmedicine.medical_treatmentImmunologychemical and pharmacologic phenomenaMice SCIDBiologyMonoclonal antibodyT-Lymphocytes RegulatoryMice03 medical and health sciences0302 clinical medicineImmune systemCancer immunotherapyMice Inbred NODImmunityNeoplasmsImmune ToleranceTumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyMice KnockoutTumor microenvironmentImmunityAntibodies MonoclonalMembrane ProteinsFOXP3General MedicineImmunosurveillance030104 developmental biology030220 oncology & carcinogenesisLeukocytes MononuclearCancer researchbiology.proteinFemaleImmunotherapyAntibodyInternational Immunology
researchProduct

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat

2018

0301 basic medicinemedicine.medical_specialtyCancer ResearchLymphomaMice03 medical and health sciences0302 clinical medicineHematology; Oncology; Cancer ResearchInternal medicineTumor MicroenvironmentmedicineAnimalsHumansHeparanase030212 general & internal medicineEnzyme InhibitorsGlucuronidaseHematologyChemistryGeneral MedicineHematologyXenograft Model Antitumor AssaysNeoplasm Proteins030104 developmental biologyOncologyCancer research
researchProduct

Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy.

2016

Various, diverse molecules contribute to the tumor microenvironment and influence invasion and metastasis. In this review, the roles of neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) in the tumor microenvironment and sensitivity to therapy will be discussed. The lipocalin family of proteins has many important functions. For example when NGAL forms a complex with MMP-9 it increases its stability which is important in cancer metastasis. Small hydrophobic molecules are bound by NGAL which can alter their entry into and efflux from cells. Iron transport and storage are also influenced by NGAL activity. Regulation of iron levels is important for survival…

0301 basic medicinemedicine.medical_treatmentDrug resistance; Iron transport; Lcn2; Lipocalins; MMP-9; NGAL; SiderocalinsAcute-Phase ProteinLipocalinLipocalinMetastasisTargeted therapyAntineoplastic Agent0302 clinical medicineNeoplasmsTumor MicroenvironmentNeoplasm MetastasisNGALProto-Oncogene ProteinMedicine (all)SiderocalinsLipocalinsNeoplasm MetastasiMatrix Metalloproteinase 9030220 oncology & carcinogenesismedicine.symptomSignal transductionMMP-9HumanProtein BindingSignal TransductionSiderocalinAntineoplastic AgentsInflammationBiologyModels Biological03 medical and health sciencesLcn2Lipocalin-2Proto-Oncogene ProteinsmedicineHumansIron transportMolecular BiologyTumor microenvironmentInnate immune systemCell Biologymedicine.disease030104 developmental biologyDrug resistanceCancer cellImmunologyCancer researchNeoplasmAcute-Phase Proteins
researchProduct

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients

2016

International audience; Despite effective targeted therapy acting on KIT and PDGFRA tyrosine kinases, gastrointestinal stromal tumors (GIST) escape treatment by acquiring mutations conveying resistance to imatinib mesylate (IM). Following the identification of NKp30-based immunosurveillance of GIST and the off-target effects of IM on NK cell functions, we investigated the predictive value of NKp30 isoforms and NKp30 soluble ligands in blood for the clinical response to IM. The relative expression and the proportions of NKp30 isoforms markedly impacted both event-free and overall survival, in two independent cohorts of metastatic GIST. Phenotypes based on disbalanced NKp30B/NKp30C ratio (Del…

0301 basic medicinemedicine.medical_treatmentImmunologyPDGFRATargeted therapy03 medical and health sciences0302 clinical medicinemedicineImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyneoplasmsOriginal ResearchTumor microenvironmentGiSTbusiness.industryCancermedicine.diseasedigestive system diseases3. Good healthImmunosurveillance030104 developmental biologyImatinib mesylateOncology030220 oncology & carcinogenesisImmunologyCancer research[SDV.IMM]Life Sciences [q-bio]/ImmunologybusinessTyrosine kinase
researchProduct

Phytochemicals Approach for Developing Cancer Immunotherapeutics

2017

Phytochemicals or their derived compounds are being increasingly recognized as potentially potent complementary treatments for cancer. Among them, some phytochemicals are being actively evaluated for use as adjuvants in anticancer therapies. For instance, shikonin and hypericin were found to induce immunogenic cell death (ICD) of specific cancer cells, and this effect was able to further activate the recognition activity of tumor cells by the host immune system. On the other hand, some derivatives of phytochemicals, such as dihydrobenzofuran lignan (Q2-3) have been found to induce the secretion of an endogenous anticancer factor, namely IL-25, from non-malignant cells. These findings sugges…

0301 basic medicinemedicine.medical_treatmentMini ReviewPharmacologyBiology03 medical and health sciences0302 clinical medicineImmune systemherbal extractCancer immunotherapymedicineCytotoxic T celltumor microenvironmentPharmacology (medical)PharmacologyTumor microenvironmentcancer immunotherapylcsh:RM1-950Cancermedicine.diseasephytochemicalslcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisCancer cellImmunogenic cell deathCancer vaccineFrontiers in Pharmacology
researchProduct

Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice.

2019

Background & Aims Nonalcoholic steatohepatitis causes loss of hepatic CD4+ T cells and promotes tumor growth. The liver is the most common site of distant metastases from a variety of malignancies, many of which respond to immunotherapy. We investigated the effects of steatohepatitis on the efficacy of immunotherapeutic agents against liver tumors in mice. Methods Steatohepatitis was induced by feeding C57BL/6NCrl or BALB/c AnNCr mice a methionine and choline–deficient diet or a choline-deficient l-amino acid–defined diet. Mice were given intrahepatic or subcutaneous injections of B16 melanoma and CT26 colon cancer cells, followed by intravenous injections of M30-RNA vaccine (M30) or intrap…

0301 basic medicinemedicine.medical_treatmentT cellT-LymphocytesArticleMetastasis03 medical and health sciencesMice0302 clinical medicineImmune systemNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasemedicineAnimalsMelanomaTumor microenvironmentMice Inbred BALB CHepatologybiologybusiness.industryLiver NeoplasmsGastroenterologyImmunotherapymedicine.diseaseMice Inbred C57BLDisease Models Animal030104 developmental biologymedicine.anatomical_structurebiology.proteinCancer research030211 gastroenterology & hepatologyImmunotherapySteatohepatitisAntibodybusinessGastroenterology
researchProduct